文献速递心境障碍

AXS-05(右美沙芬-安非他酮)治疗重性抑郁障碍的随机双盲对照试验

Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.
PubMed 文献 · Am J Psychiatry · 2022-05-18

本随机双盲多中心平行组2期试验评估AXS-05(右美沙芬-安非他酮)对比安非他酮缓释片治疗中重度重性抑郁障碍的疗效与安全性。主要终点显示AXS-05组MADRS评分改善显著优于安非他酮组,且耐受性良好。

要点

  • AXS-05组第1-6周MADRS评分平均变化显著优于安非他酮组(-13.7 vs -8.8,最小二乘均差-4.9,95%CI -3.1至-6.8)。
  • 第6周缓解率AXS-05组46.5% vs 安非他酮组16.2%(最小二乘均差30.3%,95%CI 11.2至49.4)。
  • AXS-05常见不良事件为头晕、恶心、口干、食欲下降和焦虑,未出现拟精神病效应、体重增加或性功能障碍。

核心结论

  • 在中重度重性抑郁障碍患者中,AXS-05(右美沙芬-安非他酮)较安非他酮显著改善抑郁症状,且总体耐受性良好。

研究设计与样本

  • 随机、双盲、多中心、平行组2期试验,纳入18-65岁中重度重性抑郁障碍患者,随机接受AXS-05(45mg/105mg片)或安非他酮(105mg片),前3天每日一次,之后每日两次,共6周。

主要发现

  • 疗效人群共80例(AXS-05组N=43,安非他酮组N=37)。
  • 第1-6周MADRS评分较基线平均变化:AXS-05组-13.7分 vs 安非他酮组-8.8分,最小二乘均差-4.9(95%CI -3.1至-6.8)。
  • 第2周及此后各时间点AXS-05组MADRS评分变化显著大于安非他酮组;第6周分别为-17.3分 vs -12.1分,最小二乘均差-5.2(95%CI -1.1至-9.3)。
  • 第2周及此后各时间点AXS-05组缓解率显著更高;第6周分别为46.5% vs 16.2%,最小二乘均差30.3%(95%CI 11.2至49.4)。
  • 第6周应答率(MADRS评分较基线下降≥50%):AXS-05组60.5% vs 安非他酮组40.5%,最小二乘均差19.9%(95%CI -1.6至41)。

关键数值与推荐

  • 主要终点为MADRS评分总体治疗效果(第1-6周较基线变化的平均值),在经独立评估者确认诊断和严重程度、至少接受一剂研究药物且至少有一次基线后评估的随机患者中评估。
  • AXS-05组最常见不良事件为头晕、恶心、口干、食欲下降和焦虑;未观察到拟精神病效应、体重增加或性功能障碍。

临床怎么用

  • 对于中重度重性抑郁障碍患者,AXS-05(右美沙芬-安非他酮)可能较安非他酮单药更显著改善抑郁症状,且耐受性良好。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Altered glutamatergic neurotransmission is implicated in the pathogenesis of major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to increase its bioavailability. This phase 2 trial assessed the efficacy and safety of dextromethorphan-bupropion in the treatment of major depressive disorder. METHODS: This randomized, double-blind, multicenter, parallel-group trial evaluated dextromethorphan-bupropion versus the active comparator sustained-release bupropion in patients 18-65 years old with a diagnosis of major depressive disorder of moderate or greater severity. Patients were randomly assigned to receive either dextromethorphan-bupropion (45 mg/105 mg tablet) or bupropion (105 mg tablet), once daily for the first 3 days and twice daily thereafter, for a total of 6 weeks. The primary endpoint was overall treatment effect on Montgomery-Åsberg Depression Rating Scale (MADRS) score (average of the change from baseline for weeks 1-6), assessed in all randomized patients whose diagnosis and severity were confirmed by an independent assessor and who received at least one dose of study medication and had at least one postbaseline assessment. RESULTS: Of 97 patients randomized, 17 did not have a confirmed diagnosis and severity based on the independent assessment, resulting in 80 patients in the efficacy population (dextromethorphan-bupropion, N=43; bupropion, N=37). The mean change from baseline in MADRS score over weeks 1-6 (overall treatment effect) was significantly greater with dextromethorphan-bupropion than with bupropion (-13.7 points vs. -8.8 points; least-squares mean difference=-4.9; 95% CI=-3.1, -6.8). MADRS score change with dextromethorphan-bupropion was significantly greater than with bupropion at week 2 and every time point thereafter (week 6: -17.3 vs. -12.1 points; least-squares mean difference=-5.2, 95% CI=-1.1, -9.3). Remission rates were significantly greater with dextromethorphan-bupropion at week 2 and every time point thereafter (week 6: 46.5% vs. 16.2%; least-squares mean difference=30.3%, 95% CI=11.2, 49.4). Response rates (≥50% decrease in MADRS score from baseline) at week 6 were 60.5% with dextromethorphan-bupropion and 40.5% with bupropion (least-squares mean difference=19.9%, 95% CI=-1.6, 41). Most secondary outcomes favored dextromethorphan-bupropion. The most common adverse events with dextromethorphan-bupropion were dizziness, nausea, dry mouth, decreased appetite, and anxiety. Dextromethorphan-bupropion was not associated with psychotomimetic effects, weight gain, or sexual dysfunction. CONCLUSIONS: In patients with major depression, dextromethorphan-bupropion (AXS-05) significantly improved depressive symptoms compared with bupropion and was generally well tolerated.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Tabuteau H, Jones A, Anderson A, et al. Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. Am J Psychiatry. 2022. PMID: 35582785. doi:10.1176/appi.ajp.21080800

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。